Joint FDA/EMEA application reviews, pre-approval inspections encouraged
This article was originally published in The Gold Sheet
FDA is jointly reviewing some applications with the European Medicines Agency and would like to jointly review more, agency officials on June 2 told the ISPE Washington conference. "Last week I had two teleconferences with EMEA to discuss submissions that have been submitted to both groups," said FDA's Elaine Morefield. "So prior to approval and taking action we're having discussions on trying to get similar agreement so that we're not taking different actions in different countries unless there's some need to." FDA's Rick Friedman encouraged attendees to "please tell us early if you submit a CTD to Europe and the U.S. and it's at the same time ... and you think it would be a nice candidate for a joint pre-approval inspection.
You may also be interested in...
Senior executives from Bayer outlined at a recent summit the contours of digital transformation already underway and the vital components of a successful digital team. Firms need to be able to operate technology at the “speed of business” and not “at the speed of a ticketing queue.”
A Senate Health Committee update hearing on the COVID-19 federal response was noteworthy primarily for demonstrating that FDA Commissioner Stephen Hahn appears to have salvaged the agency’s position as a voice of credibility with a key political constituency – at least for now.
The company has no development programs left in its R&D pipeline and will focus entirely on the commercialization of IBS drug Linzess while seeking late-stage assets from external sources.